Literature DB >> 3380783

Crystal and molecular structure of didemnin B, an antiviral and cytotoxic depsipeptide.

M B Hossain1, D van der Helm, J Antel, G M Sheldrick, S K Sanduja, A J Weinheimer.   

Abstract

Didemnin B, a highly active depsipeptide isolated from a Caribbean tunicate, crystallizes from chloroform/benzene in the orthorhombic space group C2221, with cell parameters a = 14.990 +/- 0.003 A, b = 22.574 +/- 0.004 A, c = 41.112 +/- 0.009 A, V = 13911.7 A3 at 138 K and a calculated density of 1.143 g/cm3 based on C57H89N7O15, 1.5C6H6.H2O and eight formula units per cell. The overall agreement factor R = 0.052 for 7699 reflections, 20 theta max = 150 degrees, Cu K-alpha radiation. The structure determination revealed that didemnin B contains an isostatine residue instead of a statine residue. The conformation of the 23-membered depsipeptide ring is stabilized by one transannular hydrogen bond. The ring does not show the antiparallel beta-pleated-sheet structure but, instead, has a fold in the shape of a bent figure-eight. The linear peptide moiety, containing N-methylleucine and lactylproline, forms a beta (II)-bend and is folded back toward the cyclic backbone, giving the overall molecule a globular character. Comparison with the structure of cyclosporin A shows distinct stereochemical differences between the two molecules. It is suggested that didemnin B and cyclosporin A are unlikely to have a common receptor binding site.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3380783      PMCID: PMC280377          DOI: 10.1073/pnas.85.12.4118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  8 in total

1.  Stereochemical criteria for polypeptides and proteins. V. Conformation of a system of three linked peptide units.

Authors:  C M Venkatachalam
Journal:  Biopolymers       Date:  1968-10       Impact factor: 2.505

2.  Didemnin B: a new immunosuppressive cyclic peptide with potent activity in vitro and in vivo.

Authors:  D W Montgomery; C F Zukoski
Journal:  Transplantation       Date:  1985-07       Impact factor: 4.939

3.  Biochemical and cellular effects of didemnins A and B.

Authors:  S L Crampton; E G Adams; S L Kuentzel; L H Li; G Badiner; B K Bhuyan
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

4.  Antitumor activity of didemnin B in the human tumor stem cell assay.

Authors:  T L Jiang; R H Liu; S E Salmon
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  Didemnin B inhibits biological effects of tumor promoting phorbol esters on mouse skin, as well as phosphorylation of a 100 kD protein in mouse epidermis cytosol.

Authors:  M Gschwendt; W Kittstein; F Marks
Journal:  Cancer Lett       Date:  1987-02       Impact factor: 8.679

6.  Antiviral and antitumor compounds from tunicates.

Authors:  K L Rinehart; J B Gloer; G R Wilson; R G Hughes; L H Li; H E Renis; J P McGovren
Journal:  Fed Proc       Date:  1983-01

7.  Mechanism of action of didemnin B, a depsipeptide from the sea.

Authors:  L H Li; L G Timmins; T L Wallace; W C Krueger; M D Prairie; W B Im
Journal:  Cancer Lett       Date:  1984-07       Impact factor: 8.679

8.  Didemnins: antiviral and antitumor depsipeptides from a caribbean tunicate.

Authors:  K L Rinehart; J B Gloer; R G Hughes; H E Renis; J P McGovren; E B Swynenberg; D A Stringfellow; S L Kuentzel; L H Li
Journal:  Science       Date:  1981-05-22       Impact factor: 47.728

  8 in total
  9 in total

Review 1.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

2.  Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting.

Authors:  D M Shin; P Y Holoye; W K Murphy; A Forman; S C Papasozomenos; W K Hong; M Raber
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Didemnin B and ternatin-4 differentially inhibit conformational changes in eEF1A required for aminoacyl-tRNA accommodation into mammalian ribosomes.

Authors:  Manuel F Juette; Jordan D Carelli; Emily J Rundlet; Alan Brown; Sichen Shao; Angelica Ferguson; Michael R Wasserman; Mikael Holm; Jack Taunton; Scott C Blanchard
Journal:  Elife       Date:  2022-10-20       Impact factor: 8.713

4.  Structural rationale for the cross-resistance of tumor cells bearing the A399V variant of elongation factor eEF1A1 to the structurally unrelated didemnin B, ternatin, nannocystin A and ansatrienin B.

Authors:  Pedro A Sánchez-Murcia; Álvaro Cortés-Cabrera; Federico Gago
Journal:  J Comput Aided Mol Des       Date:  2017-09-12       Impact factor: 3.686

Review 5.  Phase II clinical trial of didemnin B in previously treated small cell lung cancer.

Authors:  D M Shin; P Y Holoye; A Forman; R Winn; R Perez-Soler; S Dakhil; J Rosenthal; M N Raber; W K Hong
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

6.  Diphenic acid as a general conformational lock in the design of bihelical structures.

Authors:  Isabella L Karle; Punna Venkateshwarlu; Ramakrishnan Nagaraj; Akella V S Sarma; Dolly Vijay; Narahari G Sastry; Subramania Ranganathan
Journal:  Chemistry       Date:  2007       Impact factor: 5.236

7.  Decoding Mammalian Ribosome-mRNA States by Translational GTPase Complexes.

Authors:  Sichen Shao; Jason Murray; Alan Brown; Jack Taunton; V Ramakrishnan; Ramanujan S Hegde
Journal:  Cell       Date:  2016-11-17       Impact factor: 41.582

Review 8.  Natural Products Diversity of Marine Ascidians (Tunicates; Ascidiacea) and Successful Drugs in Clinical Development.

Authors:  Satheesh Kumar Palanisamy; N M Rajendran; Angela Marino
Journal:  Nat Prod Bioprospect       Date:  2017-01-17

Review 9.  Cytotoxic and antitumor peptides as novel chemotherapeutics.

Authors:  Xin Luan; Ye Wu; Yi-Wen Shen; Hong Zhang; Yu-Dong Zhou; Hong-Zhuan Chen; Dale G Nagle; Wei-Dong Zhang
Journal:  Nat Prod Rep       Date:  2020-08-10       Impact factor: 15.111

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.